http://www.medilexicon.com/medicalnews.php?newsid=239134
Boehringer Ingelheim and Eli Lilly and Company announced their results of a 24-week open label arm of a phase III study for linagliptin in initial combination with metformin at the International Diabetes Federation (IDF) World Diabetes Congress in Dubai. The results showed important reductions in blood glucose for adults with Type 2 Diabetes (T2D).
Boehringer Ingelheim and Eli Lilly and Company announced their results of a 24-week open label arm of a phase III study for linagliptin in initial combination with metformin at the International Diabetes Federation (IDF) World Diabetes Congress in Dubai. The results showed important reductions in blood glucose for adults with Type 2 Diabetes (T2D).
